AK20 / Obio Pharmaceutical - LARVOL DELTA

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - P2; N=105; Not yet recruiting; Sponsor: Akesobio Australia Pty Ltd

Clinical • New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Akesobio Australia Pty Ltd; N=40 ➔ 70

Clinical • Enrollment change • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CCL7

A Study of AK120 (IL-4Rα) in Healthy Subjects (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Akesobio Australia Pty Ltd; Not yet recruiting ➔ Recruiting; Initiation date: Feb 2020 ➔ Jun 2020

Clinical • Enrollment open • Trial initiation date • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Bioimpedance Analysis for Predicting Outcomes of Complex Decongestive Therapy for Gynecological Cancer Related Lymphedema: A Feasibility Study. (PubMed, Ann Rehabil Med) - "Our study results suggested that pre-treatment BIA could predict volume reductions after CDT in the early stages of GCRL. These findings implied that BIA value could be one possible parameter to apply in treatment outcomes prediction, during the early stage of GCRL. Therefore, further large-scale prospective studies will be beneficial."

Biomarker • Journal • Gynecologic Cancers • Oncology

A Study of AK120 in Healthy Subjects (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Akesobio Australia Pty Ltd

Clinical • New P1 trial